Shionogi Of Japan Begins Global Foray With European Cancer Drug Trial
This article was originally published in PharmAsia News
Executive Summary
The hopes of Japan's Shionogi to launch a global molecular-targeted cancer drug got under way in Europe where the company began clinical trials. The firm's S-222611 is an oral drug of low molecular weight designed to inhibit a growth factor associated with aggressive breast cancer and a growth factor related to proliferating lung-cancer cells. Shionogi's global expansion plans rest on developing a compound to a certain stage, then either finding a development partner or licensing the drug to another company to take to market. (Click here for more - a subscription may be required